key: cord-0823609-agjht48n authors: Wen, Chao; Xie, Liping; Hu, Chenxia title: Roles of mesenchymal stem cells and exosomes in interstitial cystitis/bladder pain syndrome date: 2021-12-24 journal: J Cell Mol Med DOI: 10.1111/jcmm.17132 sha: fddeeba8f7e28c401041aac47f5bc2e016ef69a9 doc_id: 823609 cord_uid: agjht48n Interstitial cystitis/bladder pain syndrome (IC/BPS) is characterized by several symptoms of higher sensitivity of the lower urinary tract, such as bladder pain/discomfort, urgency, urinary frequency, pelvic pain and nocturia. Although the pathophysiology of IC/BPS is not fully understood, the hypothesis suggests that mast cell activation, glycosaminoglycan (GAG) layer defects, urothelium permeability disruption, inflammation, autoimmune disorder and infection are potential mechanisms. Mesenchymal stem cells (MSCs) have been proven to protect against tissue injury in IC/BPS by migrating into bladders, differentiating into key bladder cells, inhibiting mast cell accumulation and cellular apoptosis, inhibiting inflammation and oxidative stress, alleviating collagen fibre accumulation and enhancing tissue regeneration in bladder tissues. In addition, MSCs can protect against tissue injury in IC/BPS by secreting various soluble factors, including exosomes and other soluble factors, with antiapoptotic, anti‐inflammatory, angiogenic and immunomodulatory properties in a cell‐to‐cell independent manner. In this review, we comprehensively summarized the current potential pathophysiological mechanisms and standard treatments of IC/BPS, and we discussed the potential mechanisms and therapeutic effects of MSCs and MSC‐derived exosomes in alleviating tissue injury in IC/BPS models. Interstitial cystitis/bladder pain syndrome (IC/BPS) is an umbrella term of chronic debilitating conditions characterized by symptoms of lower urinary tract hypersensitivity that lead to poor quality of life in IC/BPS patients. Although it is not easy to evaluate the true prevalence of IC/BPS according to the heterogenic definitions and nomenclature, approximately 3%-7% prevalence is reported according to current studies. 1 These patients always complain of chronic clinical symptoms such as bladder pain/discomfort, pelvic pain, urinary frequency, urgency and nocturia, but there is no bacterial infection in the urinary system after laboratory examinations. 2 Cameron et al. demonstrated that some women with IC/BPS also had several complaints of bladder outlet obstruction (BOO) with sensation of incomplete emptying, slow stream, straining to void and dribbling. They postulated that painful voiding was at the root of the problem with pain causing reflexive poor pelvic floor relaxation. 3 In addition, specific individuals have accompanying symptoms, including chronic stress, sleep dysfunction, anxiety and sexual dysfunction. 4 The clinical diagnosis of IC/BPS is based on these typical symptoms after exclusion of other alternative diseases with a similar presentation, including urinary tract infection, neoplasia and bladder calculi. In more recent years, IC/BPS has been reported to be closely related to other systemic pain syndromes, including chronic fatigue syndrome, fibromyalgia and irritable bowel syndrome. 5 Stem cell-based therapy has emerged as a valuable treatment to protect against tissue injury in different diseases. Stem cells can be classified into various cell types, such as mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and hematopoietic stem cells. 6 In comparison with ESCs and iPSCs, MSCs have less tumorigenicity in vivo, which enables them to be safer in clinical treatments. MSCs can be isolated from different adult tissues such as umbilical cord blood, bone marrow, adipose tissue, placenta, amniotic fluid, urine and other tissues. [7] [8] [9] [10] [11] They express low levels of major histocompatibility complex (MHC) class I molecules and MHC class II molecules, which enable them to have low immunogenicity. 12 In vitro, MSCs can differentiate into a range of cell types, including adipocytes, osteocytes, hepatocytes, chondrocytes, muscle, vascular smooth muscle cells and other connective tissues. [13] [14] [15] In response to injury signals, MSCs migrate into damaged target tissues 16, 17 and differentiate into local progenitor cells to replace ageing cells or apoptotic cells in vivo. 18, 19 In addition, the cytokines and growth factors secreted by MSCs yield beneficial outcomes in injured tissues or organs by stimulating angiogenesis and proliferation of endogenous progenitor cells but alleviating inflammatory reactions and tissue fibrosis. These paracrine effects are considered the primary therapeutic mode of action for these cells in some respects. 20 All of these mechanisms enable MSCs and their exosomes to be potential therapeutic agents for IC/BPS according to current studies. In this review, we comprehensively summarized the current potential pathophysiological mechanisms and standard treatments of IC/BPS, and we discussed the potential mechanisms and therapeutic effects of MSCs and MSC-derived exosomes in alleviating tissue injury in IC/BPS models. Although the pathophysiological mechanisms are not identifiable and not fully understood, a hypothesis suggests that mast cell activation, glycosaminoglycan (GAG) layer defects, urothelium permeability disruption, inflammation, autoimmune disorder and infection are potential mechanisms (Figure 1 ). The urothelium in bladder tissue is covered by mucopolysaccharides and consists of a basal cell layer, an intermediate layer and a superficial layer. The urothelium provides a barrier to defend the underlying tissues against urine and create a selected and specific movement of molecules towards the bladder wall. 21 The umbrella cells were denudated to develop defects in integrity and microplicae and severe pleomorphism in patients with IC/BPS. 22 Injury factors or allergic reactions induce urothelium dysfunction and result in secreting different inflammatory cytokines (vasoactive intestinal peptide [VIP] and tumour necrosis factor [TNF]), which subsequently activate mast cells. 23 Moreover, the specifically activated mast cells secrete a group of inflammatory and nociceptive factors and neurotransmitters (acetylcholine and substance P), which further promote the stimulation of other mast cells. 24 The bladder surface mucus secretes a hydrophilic GAG layer that traps water at the outer layer to form a key protective barrier at the important space between the urine and the bladder. 25 GAG molecules consist of a family of polysaccharide molecules and play critical roles in the regulation of enzymes, growth factors, protease inhibitors and cytokines. GAGs, fibronectin, elastin, collagen and laminin are known to form the basic framework of the extracellular matrix. 21 However, disruption of the GAG layer by inflammation, infection, damage, lesions and other factors results in upregulation of urothelial permeability and imbalance in urine storage. 26 Tamm-Horsfall protein (THP) is the most abundant protein that is protective in human urine and terminates in sialic acid, 27, 28 while the THP of IC/ BPS patients is less protective against urinary cations that can injure the mucus of the urothelium. 29 Potassium sensitivity is also a key mechanism in the progression of IC/BPS, since protamine sulfate administration can induce potassium absorption and injury to the bladder surface mucus. 30 The upregulation of influx of potassium ions and urothelial permeability leads to the activation of sensory afferent nerves in a vicious cycle, which contributes to the painful symptoms of IC/BPS. 31, 32 Neurogenic inflammation contributes to bladder afferent hypersensitivity and stromal fibrotic alterations via nerve-mast cell interactions. 33 Moreover, IC/BPS patients were found to have increased angiogenesis, glomerulation formation and urothelial deficiency. 22 Intriguingly, a relationship between IC/BPS and other autoimmune diseases has been reported. A large number of T cells, monocytes, mast cells, B cells and plasma cells infiltrate the urinary bladders of IC/BPS patients, 34, 35 and the ratio of inflammatory cells and T helper cells to suppressor cells is upregulated in the peripheral blood of these patients. 36 An anti-C-X-C motif chemokine ligand (CXCL)-10 antibody effectively alleviated the severity of chronic IC/BPS by locking chemokine (C-X-C motif) receptor-3 ligands and reducing the release of proinflammatory cytokines and infiltrated immune cells. 37 Upon exposure to bacterial infection, the symptoms were exacerbated, and the expression of E-cadherin was downregulated in the urothelium. 38 Removal of mucus with an acidic solution or detergents results in a significant increase in bacterial adherence or bacterial infection. 39 Targeted treatments have mixed outcomes, since the mechanisms are complex and the complicated symptoms are not easy to control. Specific treatments that target the related mechanisms are recommended. IC/BPS patients have a relatively low quality of life because of unmanageable symptoms, and the main target is to improve the quality of life of IC/BPS patients. 41 Behavioural, physical, pharmacological, endoscopic and surgical therapies must be simultaneously considered to synergistically improve the quality of life of patients. The first step in the management of patients with IC/BPS includes conservative and behavioural guidance, including timed voiding and bladder training, which serve as the foundation for long-term treatment because they are risk-free and relatively inexpensive for all patients. 42 Physiotherapy includes soft tissue massage of the pelvic floor, and myofascial trigger point release is also a good option for patients with pelvic floor dysfunction and trigger point or myofascial tenderness. 43 Pharmacotherapy includes a wide range of drugs and is currently applied in the clinic via the oral or intravesical route, while a few of them are recommended because of heterogeneity. Although amitriptyline is not licensed for application in IC/BPS, F I G U R E 1 Potential pathophysiological mechanisms of IC/BPS according to current studies this tricyclic antidepressant is used to effectively alleviate neuropathic pain when patients can tolerate a dose of at least 50 mg. 44 Pentosan polysulfate is a licensed drug for the treatment of IC/ BPS. Van et al. 45 demonstrated that pentosan polysulfate effectively alleviated discomfort symptoms such as pain, urgency and frequency compared with the placebo, and pentosan polysulfate could replace the GAG layer and inhibit mast cell degranulation. 46 Antihistamines benefit from preventing histamine release from mast cells and are potential therapeutic agents in IC/BPS patients, but evidence of efficacy is conflicting and based on low-quality studies. 47 Cyclosporin A targets T-cell activation and cytokine release and has emerged as a treatment option for IC/BPS patients. The application should be cautious because it may exert severe side effects. It is preferable for patients with refractory BPS who are not sensitive to other oral or intravesical agents. 48 Intravesical dimethylsulfoxide (DMSO) demonstrated high efficacy in symptom improvements and urodynamic and voiding diary changes with minor side effects. 49 In addition, DMSO remains the only approved drug by the Food and Drug Administration (FDA) to treat IC/BPS, and it is hypothesized to inhibit inflammatory mast cells and promote the relaxation of bladder muscles. 50 Intravesical pentosan polysulfate was reported to more significantly increase the efficacy of pentosan polysulfate in alleviating IC/BPS symptoms than oral pentosan polysulfate. 51 Intravesical lidocaine is another optional treatment with 30%-50% symptom improvements in IC/ BPS. 52 Bladder distention has served as both treatment and diagnostic tool for IC/BPS patients for many years, while the technique has an unverified outcome because of the heterogeneity in patient selection and hydrodistension techniques. 56 Meanwhile, the implanted electrode and conducting lead in sacral neuromodulation stimulate the afferent sacral nerves when they exit the sacral foramina, which obviously alleviates symptoms of pelvic pain, frequency, nocturia and urgency in IC/BPS patients. 57 However, some patients with implantation of the device found that the symptoms were aggravated, which indicates that revision or explanation of the device is necessary. Radical surgery is the last resort option for severe and disabling IC/BPS patients who are not sensitive to other treatments. Most recently, in 2021, a systematic review concluded that 77% of 448 IC/ BPS patients had symptomatic improvement after they underwent radical surgery, and total cystectomy with orthotopic neobladder formation had the highest clinical response compared to subtotal cystectomy with cystoplasty and urinary diversion alone. 58 Although there are various treatment tools for IC/BPS patients, there are still no definite treatments in terms of recurrence, side effects or lack of response. IC/BPS is a chronic condition that may be controlled but not cured. It is necessary to investigate new and safer agents to inhibit pathophysiological processes. Although there have been no definitive treatments to cure this heterogeneous disease until now, MSCs have emerged as a new therapeutic agent in IC/BPS. Bladder dysfunction is an excellent candidate for stem cell therapy due to its chronic nature and high prevalence. 59 Compared to radical surgery, MSC transplantation is easier to manipulate. In comparison with pharmacological agents, they are pleiotropic and have no severe side effects. MSCs can be isolated from autologous tissue without rejection reaction. Moreover, cell-free therapy based on MSC-derived exosomes is an emerging treatment that benefits from abundant anti-inflammatory and anti-immune cytokines. Mesenchymal stem cells have been proven to protect against tissue injury in IC/BPS via different mechanisms (Table 1) transplantation. 70 We have found that the anti-inflammatory and immunoregulatory capacities of MSCs are more important and widely studied after we take a panoramic view of the situation from the current studies. Partial BOO is a common pathological condition induced by sev- This work was supported by the National Natural Science Foundation of China (no. 81700553) and Zhejiang basic public welfare research programme (no. LGF20H030008). The authors declare that they have no conflict of interest. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States Treatment of interstitial cystitis Bladder outlet obstruction in painful bladder syndrome/interstitial cystitis Psychosocial phenotyping in women with interstitial cystitis/painful bladder syndrome: a case control study A MAPP network case-control study of urological chronic pelvic pain compared with nonurological pain conditions Mesenchymal stem cells: potential application for the treatment of hepatic cirrhosis Comparative analysis of human mesenchymal stem cells derived from bone marrow, placenta, and adipose tissue as sources of cell therapy Influence of the mesenchymal stromal cell source on the hematopoietic supportive capacity of umbilical cord blood-derived CD34(+)-enriched cells Silencing VEGFR-2 hampers odontoblastic differentiation of dental pulp stem cells miR-351-3p promotes rat amniotic fluid-derived mesenchymal stromal cell proliferation via targeting the coding sequence of Abca4 Verification of mesenchymal stem cell injection therapy for interstitial cystitis in a rat model Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo Mesenchymal stem cells on horizon: a new arsenal of therapeutic agents Eminent sources of adult mesenchymal stem cells and their therapeutic imminence Injectable gel form of a decellularized bladder induces adiposederived stem cell differentiation into smooth muscle cells in vitro ATP-Nlrp3 inflammasomecomplement cascade axis in sterile brain inflammation in psychiatric patients and its impact on stem cell trafficking Cardiac stem cell patch integrated with microengineered blood vessels promotes cardiomyocyte proliferation and neovascularization after acute myocardial infarction A novel view of the adult stem cell compartment from the perspective of a quiescent population of very small embryonic-like stem cells Sirt1 regulates DNA methylation and differentiation potential of embryonic stem cells by antagonizing Dnmt3l Paracrine mechanisms in adult stem cell signaling and therapy pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition Mast cells, neuropeptides and inflammation Mast cell involvement in interstitial cystitis: a review of human and experimental evidence Bladder surface glycosaminoglycans: an epithelial permeability barrier Modulation of epithelial permeability by extracellular macromolecules Uromodulin: a unique 85-kilodalton immunosuppressive glycoprotein isolated from urine of pregnant women Characterization and separation of an inhibitor of viral hemagglutination present in urine The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis Abnormal urinary potassium metabolism in patients with interstitial cystitis Alteration of urothelial inflammation, apoptosis, and junction protein in patients with various bladder conditions and storage bladder symptoms suggest common pathway involved in underlying pathophysiology Interstitial cystitis/bladder pain syndrome: the evolving landscape, animal models and future perspectives Clinical features and spectrum of light microscopic changes in interstitial cystitis Lymphocyte sub-populations in the bladder wall in normal bladder, bacterial cystitis and interstitial cystitis Interstitial cystitis: bladder mucosa lymphocyte immunophenotyping and peripheral blood flow cytometry analysis The severity of experimental autoimmune cystitis can be ameliorated by anti-CXCL10 Ab treatment Increased urothelial cell apoptosis and chronic inflammation are associated with recurrent urinary tract infection in women Role of surface mucin in primary antibacterial defense of bladder Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot Treatment costs of bladder pain syndrome/interstitial cystitis in Austria: a pharmacoeconomic approach following current guidelines Behavioral therapy for the treatment of refractory interstitial cystitis Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/ painful bladder syndrome Efficacy of pentosan polysulfate for the treatment of interstitial cystitis/bladder pain syndrome: results of a systematic review of randomized controlled trials The role of the bladder surface in interstitial cystitis/painful bladder syndrome Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial Clinical management of bladder pain syndrome/interstitial cystitis: a review on current recommendations and emerging treatment options A controlled study of dimethyl sulfoxide in interstitial cystitis Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: a review Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management Systematic review and meta-analysis of intravesical hyaluronic acid and hyaluronic acid/chondroitin sulfate instillation for interstitial cystitis/painful bladder syndrome A randomized, openlabel, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment -a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial A systematic review of the literature on cystodistension in bladder pain syndrome Sacral neuromodulation for refractory bladder pain syndrome/interstitial cystitis: a global systematic review and meta-analysis A systematic review of surgical interventions for the treatment of bladder pain syndrome/ interstitial cystitis Stem cell therapy for interstitial cystitis/ bladder pain syndrome Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder Longitudinal intravital imaging of transplanted mesenchymal stem cells elucidates their functional integration and therapeutic potency in an animal model of interstitial cystitis/bladder pain syndrome Improved efficacy and in vivo cellular properties of human embryonic stem cell derivative in a preclinical model of bladder pain syndrome Mesenchymal stem cell therapy alleviates interstitial cystitis by activating Wnt signaling pathway Injection of dental pulp stem cells promotes healing of damaged bladder tissue in a rat model of chemically induced cystitis Umbilical cord-derived mesenchymal stem cells alleviated inflammation and inhibited apoptosis in interstitial cystitis via AKT/mTOR signaling pathway Human umbilical cord mesenchymal stem cell therapy mitigates interstitial cystitis by inhibiting mast cells Therapeutic effect of urine-derived stem cells for protamine/lipopolysaccharide-induced interstitial cystitis in a rat model Mesenchymal stem cells protect against the tissue fibrosis of ketamine-induced cystitis in rat bladder Bladder wall injection of mesenchymal stem cells ameliorates bladder inflammation, overactivity, and nociception in a chemically induced interstitial cystitislike rat model TGF-β/MAPK signaling mediates the effects of bone marrow mesenchymal stem cells on urinary control and interstitial cystitis after urinary bladder transplantation Developing and validating a new nomogram for diagnosing bladder outlet obstruction in women Mesenchymal stem cell therapy inhibited inflammatory and profibrotic pathways induced by partial bladder outlet obstruction and prevented high-pressure urine storage Treatment for chronic ischaemiainduced bladder detrusor dysfunction using bone marrow mesenchymal stem cells: an experimental study Comparison of the therapeutic effects of adipose-derived and bone marrow mesenchymal stem cells on erectile dysfunction in diabetic rats A comparison of the use of adipose-derived and bone marrow-derived stem cells for peripheral nerve regeneration in vitro and in vivo Mesenchymal stromal cells from different parts of umbilical cord: approach to comparison & characteristics Synergistic effects of N-acetylcysteine and mesenchymal stem cell in a lipopolysaccharide-induced interstitial cystitis rat model Melatonin treatment further improves adipose-derived mesenchymal stem cell therapy for acute interstitial cystitis in rat Efficacy of combination therapy with pentosan polysulfate sodium and adipose tissue-derived stem cells for the management of interstitial cystitis in a rat model Mesenchymal stem cell-derived exosomes for clinical use Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses MSC exosome as a cell-free MSC therapy for cartilage regeneration: implications for osteoarthritis treatment MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity Platelet membrane and stem cell exosome hybrid enhances cellular uptake and targeting to heart injury Exosome therapeutics for COVID-19 and respiratory viruses. View (Beijing) Hypoxia inducible factor-1α potentiates jagged 1-mediated angiogenesis by mesenchymal stem cell-derived exosomes Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling A new era of cardiac cell therapy: opportunities and challenges Conditioned medium derived from mesenchymal stem cells culture as a intravesical therapy for cystitis interstitials Mesenchymal stem cells inhibit hypoxia-induced inflammatory and fibrotic pathways in bladder smooth muscle cells Induction of urothelial cell proliferation by fibroblast growth factor-7 in RAG1-deficient mice MicroRNAs may mediate the down-regulation of neurokinin-1 receptor in chronic bladder pain syndrome Inhibition of microRNA-214 promotes epithelial-mesenchymal transition process and induces interstitial cystitis in postmenopausal women by upregulating Mfn2 Exosomes derived from miR-214-enriched bone marrow-derived mesenchymal stem cells regulate oxidative damage in cardiac stem cells by targeting CaMKII Roles of mesenchymal stem cells and exosomes in interstitial cystitis/ bladder pain syndrome